Overactive Bladder Category Switch Prospects Questioned By Indevus
This article was originally published in The Tan Sheet
Executive Summary
Self-selection problems will likely complicate potential Rx-to-OTC switches in the overactive bladder (OAB) category, Indevus Pharmaceuticals execs maintained during an Aug. 9 third quarter earnings call